Silexion Therapeutics’ Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer

All NewsMarch 5, 2025

Silexion’s SIL204 reduced tumor growth and metastases in pancreatic cancer models, showing strong efficacy across KRAS mutation profiles in preclinical studies.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent